Latest Developments in Bioavailability, Drug Delivery and Optimization of Drug Design to be Presented by Catalent Experts at AAPS Annual Convention

Share Article

A team of senior drug development and delivery experts from Catalent Pharma Solutions (Booth 624), will host multiple thought-leadership discussions, present scientific papers, and exhibit at the forthcoming 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs from October 25th to October 29th, at the Orange County Convention Center, Orlando, FL. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products.

A team of senior drug development and delivery experts from Catalent Pharma Solutions (Booth 624), will host multiple thought-leadership discussions, present scientific papers, and exhibit at the forthcoming 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs from October 25th to October 29th, at the Orange County Convention Center, Orlando, FL. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products.

Catalent will also be showcasing its new OptiForm® Solution Suite platform, designed to match the best, most innovative, drug delivery technologies to each developmental molecule, with the goal of providing optimal candidate formulations for animal PK studies in twelve weeks. Combining four technologies, including advanced parallel screening, OptiForm Solution Suite aims to enhance drug bioavailability and to accelerate more molecules to the clinic and beyond.

On Monday, October 26th at 12:00 p.m., David Igo, Catalent’s Director, Product Development, will present "Accelerating Early Stage Drug Development: New Approaches and Enabling Technologies," while on Wednesday, October 28th, at 2:40 p.m., Dr. Leon Xu, Director, Bioconjugation and Chemical Development, will discuss "The Manufacture and Analytics of Site Specifically Modified ADCs Using a SMARTag™ Platform".

In addition to the two speakers, the Catalent Applied Drug Delivery Institute is to host a seminar entitled “Accelerating Development for Challenging Compounds: Enabling Technologies, Parallel Processes, Rigorous Data” on Monday October 26th, running from 1:00 p.m. until 4:00 p.m. During the session, Cornell Stamoran, VP, Corporate Strategy, and a founder of the Institute, will discuss innovator challenges to optimizing drug design, followed by the latest developments in enabling technologies, including lipid based delivery systems, particle size engineering, amorphous systems and solid state optimization.

Catalent will also present twenty five scientific papers at the AAPS meeting on a broad spectrum of topics, including solid solutions in hot melt extrusions, modified and controlled release capsule development, the latest softgel technologies, micronization, lipid based drug delivery, and retrospective QbD.

A full list of poster topics and presentation times can be found at http://www.catalent.com/index.php/news-events/events/2015-AAPS-Annual-Meeting-and-Exposition.

To arrange a meeting with any of the Catalent team at AAPS, please contact Richard Kerns at NEPR- richard@nepr.eu.

About Catalent Applied Drug Delivery Institute
Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website